Ambucaine

Ambucaine

SCHEMBL82280

CCCCOc1cc(N)ccc1C(=O)OCCN(CC)CC

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 8/20 0.91
SCN2A Q99250 8/20 0.91
SCN3A Q9NY46 8/20 0.91
CYP2D6 P10635 6/20 0.91
CYP1A2 P05177 6/20 0.91
HRH3 Q9Y5N1 4/20 0.67
KCNH2 Q12809 4/20 0.67
MAOA P21397 3/20 0.67
HTR3A P46098 3/20 0.67
CHRM2 P08172 2/20 0.67
CHRM3 P20309 1/20 0.67
HTR2C P28335 1/20 0.67
CHRNA4 P43681 1/20 0.67
TSHR P16473 5/20 0.65
SLC6A3 Q01959 2/20 0.65
SLC6A2 P23975 1/20 0.65
HIF1A Q16665 1/20 0.65
RAD52 P43351 1/20 0.64
CYP3A4 P08684 4/20 0.57
CYP2C19 P33261 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ambucaine SCHEMBL1007224 0.99 CYP2D6 (0.88) SCN1ASCN2ASCN3ACYP2D6CYP1A2
Propoxycaine SCHEMBL83073 0.95 SCN1A (1.00) SCN1ASCN2ASCN3ACYP2D6CYP1A2
Propoxycaine SCHEMBL29353209 0.95 SCN1A (1.00) SCN1ASCN2ASCN3ACYP2D6CYP1A2
Propoxycaine SCHEMBL24720 0.94 SCN1A (0.98) SCN1ASCN2ASCN3ACYP2D6CYP1A2
Propoxycaine SCHEMBL1651061 0.93 SCN1A (0.95) SCN1ASCN2ASCN3ACYP2D6CYP1A2
Ambucaine SCHEMBL3660746 0.91 SCN1A (0.76) SCN1ASCN2ASCN3ACYP2D6CYP1A2
SCHEMBL14304169 0.89 CYP1A2 (0.72) SCN1ASCN2ASCN3ACYP2D6CYP1A2
SCHEMBL10246464 0.88 CYP1A2 (0.70) SCN1ASCN2ASCN3ACYP2D6CYP1A2
SCHEMBL5925620 0.87 CYP2D6 (0.77) SCN1ASCN2ASCN3ACYP2D6CYP1A2
Propoxycaine SCHEMBL8683800 0.87 CYP1A2 (0.83) SCN1ASCN2ASCN3ACYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT UNIV KOREA RES & BUS FOUND (KR) 2026-04-30 US claimed
WO-2025235864-A1 COATED NEEDLE ADMINISTRATION SYSTEMS EVOLUS, INC. (US) 2025-11-13 WO claimed
US-20250319025-A9 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-16 US claimed
EP-4578441-A1 TREATMENT OF LOCALIZED PAIN PlantTec Medical GmbH (DE) 2025-07-02 EP claimed
US-20250205278-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING ABBOTT NICHOLAS L (US) 2025-06-26 US claimed
WO-2025128639-A1 HYDROGELS COMPRISING PROTEIN-STABILIZED NANOPARTICLES FOR EXTENDED RELEASE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-19 WO claimed
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics BIOPOLIMERI S.R.L. (IT) 2025-06-17 US claimed
US-20250186364-A1 COMBINATION OF ANTISPASMODIC AND ANESTHETIC AGENTS FOR TOPICAL PRODUCTS AND THEIR METHOD OF USE PRIMA INNOVATIONS, LLC 2025-06-12 US claimed
WO-2025075976-A2 METHYL-BRANCHED LIPOSOMES FOR SUSTAINED DRUG DELIVERY THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-04-10 WO claimed
EP-4362994-B1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S R L (IT) 2025-03-12 EP claimed
US-6432986-B2 INTRANOSALLY ADMINISTERING OF ANESTHETICS BHL PATENT HOLDINGS LLC 2002-08-13 US claimed
US-20010055607-A1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES BHL PATENT HOLDINGS LLC 2001-12-27 US claimed
WO-2001080797-A1 MEDICATED WRAP HYSON MORTON I (US) 2001-11-01 WO claimed
WO-2001043733-A2 COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION LEVIN BRUCE H (US) 2001-06-21 WO claimed
US-20010004644-A1 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation LEVIN BRUCE H (US) 2001-06-21 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5776952-A Method and composition for topical therapy of back pain and muscle tension AMERICAN PHARMED LABS, INC. (US) 1998-07-07 US claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010055607-A1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES TNNC1, KIT, PDE3A SCN1A 43/4885SCN2A 137/4885SCN3A 79/4885
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics CD44, HCAR3, HCAR2 SCN1A 2618/4885SCN2A 2486/4885SCN3A 2849/4885
US-20010004644-A1 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation CXCR5, CCL5, C5AR2 SCN1A 2794/4885SCN2A 3499/4885SCN3A 3081/4885
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT CES2, DAGLA, ACHE SCN1A 1562/4885SCN2A 501/4885SCN3A 401/4885
US-20250319025-A9 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF PHOSPHO1, SGMS1, LIPA SCN1A 2895/4885SCN2A 3824/4885SCN3A 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.